Consolidated net profit declined 27.4% Year on Year (YoY) in 2020, compared to EGP 671.45 million in 2019.
The company’s standalone net profit went down 30.9% YoY to EGP 422.83 million during the January-December period of 2020, compared to EGP 611.55 million in the corresponding period of 2019.
The pharmaceutical company reported a 35% YoY decline in its consolidated net profit in the first nine months of 2020, achieving EGP 339.46 million, compared to EGP 522.19 million in the prior-period year.
EIPICO is an Egypt-based public shareholding company that operates in the pharmaceutical industry. It is a manufacturer and exporter of pharmaceuticals and holds license agreements with a group of international pharmaceutical companies to produce their products locally and replace the imported ones.
Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an “as is” and “as available” basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.
Get Zawya's daily newsletter for insightful and exclusive Middle East perspectives on business and finance. SUBSCRIBE NOW